Objective: To investigate the potential of inflammation to induce new adipose tissue formation in the in vivo environment. Methods and results: Using an established model of in vivo adipogenesis, a silicone chamber containing a Matrigel and fibroblast growth factor 2 (1 mg/ml) matrix was implanted into each groin of an adult male C57Bl6 mouse and vascularized with the inferior epigastric vessels. Sterile inflammation was induced in one of the two chambers by suspending Zymosan-A (ZA) (200-0.02 mg/ml) in the matrix at implantation. Adipose tissue formation was assessed at 6, 8, 12 and 24 weeks. ZA induced significant adipogenesis in an inverse dose-dependent manner (Po0.001). At 6 weeks adipose tissue formation was greatest with the lowest concentrations of ZA and least with the highest. Adipogenesis occurred both locally in the chamber containing ZA and in the ZA-free chamber in the contralateral groin of the same animal. ZA induced a systemic inflammatory response characterized by elevated serum tumour necrosis factor-a levels at early time points. Aminoguanidine (40 mg/ml) inhibited the adipogenic response to ZA-induced inflammation. Adipose tissue formed in response to ZA remained stable for 24 weeks, even when exposed to the normal tissue environment.
Introduction
Obesity and the metabolic syndrome are characterized by a state of chronic low-grade inflammation typified by raised plasma levels of proinflammatory cytokines, particularly tumour necrosis factor-a (TNF-a) and interleukin-6 (IL-6) [1] [2] [3] and elevated leucocyte counts. 4, 5 Adipose tissue has been identified as the source of many of these proinflammatory cytokines 6 and is progressively infiltrated by inflammatory cells with increasing obesity. 7 Although the causal relationship between inflammation and obesity is incompletely understood several authors have hypothesized that chronic low-grade inflammation may drive adipogenesis. 8, 9 However, inflammatory cytokines have been shown in vitro to inhibit preadipocyte differentiation [10] [11] [12] and promote dedifferentiation and apoptosis in both preadipocytes and mature adipocytes. 13, 14 To what extent these results can be extrapolated to the in vivo environment remains uncertain. For instance, chronic stimulation of lymph nodes with bacterial lipopolysaccharide (LPS) in rats leads to hyperplasia and hypertrophy of local adipose tissue surrounding the lymph node. 15 We therefore aimed to assess the adipogenic potential of inflammation in vivo, in an established Matrigel-based model of adipogenesis. Matrigel, a commercially available preparation of the extracellular matrix of the Engelbreth-HolmSwarm mouse sarcoma, supplemented with fibroblast growth factor 2 (FGF-2) is strongly adipogenic when injected into the subcutaneous layer. 16 At this site adipogenesis occurs through the recruitment of adipose precursor cells from adipose tissue that directly abuts the Matrigel plug. 16 We have demonstrated that isolating the Matrigel from the surrounding tissues in a closed silicone chamber, supplied by a dedicated vascular pedicle, largely prevents adipogenesis while still maintaining a satisfactory angiogenic response. 17 This model permits the investigation of systemic influences on adipogenesis without the presence of confounding local factors. We chose to induce inflammation in the chamber with Zymosan-A (ZA), a polysaccharide preparation of the cell wall of Saccharomyces cerevisiae rich in b-1,3-glucan. 18 ZA
consists of large, insoluble particles of approximately 3 mm diameter, which promote trapping in a gel matrix, localizing the inflammatory focus. Its ligand interactions are relatively well documented. ZA elicits an inflammatory response by activating Toll-like receptors 2, expressed by macrophages 19 and neutrophils. 20 Macrophages require direct contact with ZA particles to activate nuclear factor-kB and trigger cytokine production, though contact with a single particle is sufficient to do so. 21 ZA is largely cleared through phagocytosis by macrophages and neutrophils, which further extends the inflammatory response. 22, 23 Aminoguanidine (AG), a relatively selective inhibitor of inducible nitric oxide synthase (iNOS), has been shown to attenuate ZA-induced inflammation in a number of in vivo models. [24] [25] [26] As inflammation in obesity and the metabolic syndrome is a systemic rather than purely local phenomenon, we hypothesized that localized inflammation in response to ZA would result in a systemic inflammatory and thence adipogenic response. Serum TNF-a and IL-6 levels were assayed as a measure of systemic inflammation. Each animal had two Matrigel-filled chambers implanted, one containing ZA and the other not. The ZA-free chamber was used to test for a systemic adipogenic response. Specifically, would inflammation induced by ZA in one chamber result in adipogenesis in a distant chamber in the same animal?
We demonstrate here that in an in vivo chamber model of adipogenesis, in the presence of Matrigel and FGF-2, ZA induces new fat formation in a dose-dependent manner. We found that adipo-induction occurred not only locally at the site of ZA, but also in ZA-free chambers in the same animal. ZA-induced adipogenesis was inhibited by AG. We found that adipose tissue once formed remained stable for at least 24 weeks, even when the silicone chamber casing was removed.
Materials and methods

Materials
Growth factor-reduced Matrigel was purchased from BD Biosciences (Bedford, MA, USA) and supplemented with heparin (80 U/ml) (Heparin Sodium Injection, USP (1000 U/ml) Pharmacia & Upjohn, Kalamazoo, MI, USA) and FGF-2 (1 mg/ml) (recombinant human FGF-2, Peprotech Inc., Burlingame, CA, USA). ZA and AG were obtained from Sigma-Aldrich (Sydney, Australia) and suspended in sterile normal saline immediately before use at a concentration determined by the experiment. The resulting ZA and or AG solution was added at low volume to the Matrigel (10 ml per 1000 ml) and agitated to ensure a uniform suspension. Mouse IL-6 and mouse TNF-a Quantikine immunoassay kits were purchased from R&D Systems (Minneapolis, MN, USA).
Animals and surgery
Male C57Bl6 mice (20-26 g body weight) were used in all experiments. Surgery was performed in sterile conditions under general anaesthesia (induced by an intraperitoneal injection of chloral hydrate, 0.4 mg/g body weight) and with the ethical approval of the St Vincent's Hospital Animal Ethics Committee. Animals were housed in social groups of 4-6, fed normal chow and water ad libitum and weighed prior surgery and again at harvest.
Chambers consisting of 5 mm lengths of silicone laboratory tubing (3.35 mm internal diameter, 44 ml volume; DowCorning Corp., Midland, MI, USA) were inserted into both groins of the mouse as previously described. 17 Briefly, the superficial epigastric vessels were exposed via a transverse groin incision and dissected free of their investing fascia for a distance of approximately 1 cm from their origin at the femoral vessels. The split silicone tube chamber was then prised open, placed around the vessels and allowed to spring closed. It was anchored to the underlying muscle with a 10/0 nylon microsuture. The proximal aperture and longitudinal seam of the chamber were sealed with bone wax (Ethicon, Somerville, NJ, USA) and the chamber filled with Matrigel and ZA, as detailed below. Following this the distal aperture of the chamber was also sealed, creating a 'closed' chamber ( Figure 1 ). 17 The construct was then carefully returned to the dissected pocket within the groin and the wound closed with metal clips. Matrigel chambers without ZA was also included (n ¼ 6, ZAtreated groups; n ¼ 9, control group). The tissue contents of the chambers (termed constructs) were harvested at 6 weeks following insertion.
Immunoassays of serum IL-6 and TNF-a Bilateral chambers were inserted as above. Ipsilateral chambers contained ZA doses at the extremes of the dose-response study (200 and 0.02 mg/ml). A control group without ZA in the ipsilateral chamber was also included (n ¼ 4 per group). Animals were killed and blood taken at 2 and 5 days following insertion. Serum was prepared from blood samples following standard methods. Enzyme-linked immunosorbent assays for mouse IL-6 and mouse TNF-a using Quantikine immunoassay kits were performed as per the manufacturer's instructions. Plates were read immediately on a Multiskan microplate reader (Multiskan RC, Pathtech, Preston, Vic., Australia) set at l450 nm absorbance with a correction reading set at l550 nm. All measurements and calculations were performed using Genesis 2 plate reading software (Version 3.04, Lifesciences, Cambridge, UK) and values were translated to pg/mg of matrix.
Aminoguanidine inhibition of ZA-induced adipogenesis Bilateral chambers were inserted as above. As before, the ipsilateral chamber received Matrigel with 0.2 mg/ml ZA and the contralateral chamber was filled with Matrigel alone, without ZA. The dose of 0.2 mg/ml ZA for the ipsilateral chamber was chosen from the results of the ZA doseresponse assay, as this concentration resulted in the maximum adipogenesis in both the ipsilateral and contralateral constructs. AG at 40 mg/ml was added to either the ipsilateral or contralateral chamber. Constructs were harvested at 6 weeks following insertion and assessed for adipose content (n ¼ 8 per group).
Long-term stability of inflammation induced adipose tissue
Repeat bilateral chambers models were established with a concentration of ZA 1 mg/ml in the ipsilateral chamber (dose derived from a pilot study, results not shown). Constructs were harvested at 8, 12 and 24 weeks. A further group was reoperated on at 12 weeks, removing the silicone chamber but leaving the developing construct in situ, attached to its vascular pedicle. The construct was marked with loose 10/0 nylon microsutures to facilitate its retrieval at harvest. This group was then harvested 12 weeks later, 24 weeks following chamber insertion (n ¼ 8, control groups all time points; n ¼ 9, ZA-treated groups all time points; n ¼ 10, chamber removal at 12 weeks, harvest at 24 weeks group).
Construct harvest and assessment
At harvest, animals were anaesthetized without recovery, weighed and the contents of each chamber removed, after assessment of the patency of the epigastric vessel pedicle. This was determined by observing active bleeding from both cut ends of the pedicle. The volumes of patent tissue constructs were determined by volume displacement in normal saline at room temperature. 27 Constructs were fixed in 4% paraformaldehyde, dehydrated through a graded alcohol series and paraffin embedded. Each construct was serially sectioned along its longitudinal axis to completion. Every 20th 5 mm section was stained with haematoxylin and eosin (H&E) and point-counted using digital video imaging (JVC, TK C1480E) with an automated, systematic pointcounting system (CAST system, Olympus, Denmark) to determine the percentage of adipose tissue, residual Matrigel, fibrous granulation tissue and other (mostly vascular) tissue in each construct. Absolute volumes of each tissue type were calculated from the proportion of each tissue and the wet volume of the construct. Shrinkage due to histological processing was assumed to be constant for all tissue types present and for each experimental group. S100 immunohistochemistry was used in conjunction with cell morphology to confirm the identity of developing and mature adipocytes. 28 Construct neutrophil counts were determined for the ZA dose-response assay. A single longitudinal section, taken at the level of the pedicle, from each chamber was counted. Neutrophils were identified by their unique morphology on H&E staining. Sections were frame-counted (100 frames/ section at Â 100 magnification) using digital video imaging with the automated CAST counting system to determine the density of neutrophils per mm 2 of tissue.
Immunohistochemistry
Immunohistochemistry was performed on 5 mm 4% paraformaldehyde-fixed, paraffin-embedded tissue sections. Monocyte/macrophages were detected using rat anti-mouse F4/80 monoclonal antibodies (Abcam, Cambridge, UK). Adipocytes were identified with rabbit anti-cow S-100 purified immunoglobulin (Dako, CA, USA), which crossreacts strongly with mouse S-100 A and B. Rabbit anti-rat biotinylated immunoglobulin G (IgG, Dako) was used as a secondary antibody for anti-F4/80 and swine anti-rabbit biotinylated IgG was employed for anti-S100. Antibody detection was completed with a streptavidin-horseradish peroxidise conjugate (Dako) and visualized with Dako DAB chromagen (Dako) in all cases.
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Statistical analyses
Statistical analyses were performed using Minitab 14.2 statistical software (Minitab Inc., PA, USA). Results were compared using a mixed factorial two-way analysis of variance (ANOVA). For the adipogenic ZA dose-response assay a significant interaction between ZA dose and chamber side (ipsilateral versus contralateral) prevented further analysis by two-way ANOVA, hence all ipsilateral chambers were compared using one-way ANOVA and a post hoc Dunnett's test. Contralateral chambers were compared in the same way. For comparisons between sides within a single group at one ZA dose a paired t-test was used. All other assays were analysed using a mixed factorial two-way ANOVA with a post hoc Dunnett's test where appropriate. P-values o0.05 were considered statistically significant. Standard errors (7) of means are given throughout.
Results
Adipogenic ZA dose-response assay Mice in all groups gained weight over the 6-week course of the experiment. The greatest weight gain was in controls (mean 5.270.5 g, 21.4% of initial total body weight) and the least was in group receiving the highest dose of ZA (mean 3.470.5 g, 12.9% of initial total body weight). There was no statistically significant difference in body weight gain between any of the groups. Overall, ZA induced significant neo-adipogenesis in both ipsilateral and contralateral constructs at 6 weeks in terms of the percentage adipose tissue content (F ¼ 11.31, Po0.0001) and absolute adipose volume (F ¼ 7.64, Po0.0001) ( Figures  2a, b and 3a-d) . This new adipose tissue was characterized by S100-positive mature adipocytes containing a single lipid droplet with typical signet-ring nucleus and differentiating S100-positive preadipocytes-containing clusters of rounded lipid droplets (Figure 4a ). Even control group constructs contained some adipose tissue (ipsilateral constructs 11.373.1%, 1.2170.46 ml; contralateral constructs 9.972.5%, 0.9170.19 ml) (Figures 3e and f) . The adipose content of constructs from the highest ZA concentration (200 mg/ml) group was statistically indistinguishable from controls, but as the ZA dose reduced, the adipose content of constructs significantly increased to a maximum of 44.475.3% (5.9371.05 ml) in the lowest ZA dose (0.02 mg/ml) ipsilateral constructs (Po0.001, one-way ANOVA) and 41.074.2% (5.1571.37 ml) in the ZA dose (0.2 mg/ml) contralateral constructs (Po0.001, one-way ANOVA).
There was no difference in adipose tissue content between ipsilateral and contralateral constructs at 6 weeks, with the exception of the lowest ZA dose (0.02 mg/ml), in which it was significantly greater in the ipsilateral (44.475.3%, 5.9371.05 ml) than contralateral constructs (25.575.0%, 2.3470.68 ml) (Po0.05, paired t-test; Figures 2a and b) . Not only did the adipose content of constructs increase as the ZA dose was reduced, but the total volume of constructs also increased (Figure 2c ). The volume of ipsilateral constructs from groups receiving the lowest concentrations of ZA (0.2 and 0.02 mg/ml) was significantly greater than those from the maximum ZA concentration group (200 mg/ml) (Po0.01, one-way ANOVA). There was a similar, non-significant, trend among contralateral constructs. Constructs from controls were also larger than high ZA dose (200 mg/ml) ipsilateral constructs (Po0.05, one-way ANOVA, Dunnett's post hoc test). Tissue composition differed markedly between the two. In controls, 60.973.3% (6.6970.80 ml) of ipsilateral and 67.573.1% (7.1070.87 ml) of contralateral constructs consisted of relatively acellular Matrigel, whereas it represented only 35.472.8% (2.3770.27 ml) of ipsilateral and 36.473.6% (2.2770.36 ml) of contralateral constructs in the 200 mg/ml ZA group (Po0.005, one-way ANOVA, Dunnett's post hoc test, for percentage and volume of adipose tissue on both ipsilateral and contralateral sides), the remainder comprising of new adipose tissue and fibrous granulation tissue. Indeed, Figure 2 Adipogenic dose-response to Zymosan-A (ZA) at 6 weeks. The percentage (a) and absolute (b) adipose content of constructs from ZA-treated groups increased significantly when compared to controls (ZA ¼ 0 mg/ml) (**Po0.005, ***Po0.001 (both ipsilateral and contralateral constructs), *Po0.05 (both sides in (a), contralateral constructs only in (b), w Po0.0001 (ipsilateral constructs only) all compared to controls). There was no difference between ipsilateral and contralateral constructs, with the exception of the group receiving ZA 0.02 mg/ml ( y Po0.05). (c) Mean construct tissue composition at 6 weeks. The ZA concentration quoted on the x axis for the contralateral chambers corresponds to the ZA concentration of the ipsilateral chamber in same animal. No contralateral chamber contained ZA (n ¼ 6, ZA-treated groups; n ¼ 9, control group).
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GPL Thomas et al the volume of Matrigel in control constructs was significantly greater than in any of the ZA-treated groups (Po0.01 (ZA 0.02 mg/ml), Po0.005 (all other ZA groups) one-way ANOVA, Dunnett's post hoc test, both ipsilateral and contralateral sides) (Figure 2c ). Matrigel content was largely uniform between ZA-treated groups, with a non-significant trend of increasing Matrigel content at lower ZA doses. The fibrous tissue content of constructs was similar in all groups. Neutrophils were present in all constructs and significantly elevated in high ZA dose groups, 200 mg/ml ZA group (449762 neutrophils/mm There was no significant difference in neutrophil counts between ipsilateral and contralateral constructs in any group.
Other inflammatory cells were also present in constructs. Aggregations of lymphocytes were present within the Matrigel and adipose tissue of constructs. F4/80-positive monocyte/macrophages were present at high densities Inflammation and adipogenesis GPL Thomas et al throughout the constructs of all groups. Where adipose tissue was present they were found to be in close proximity to the newly formed adipocytes where they were often arranged in an irregular pattern around an adipocyte (Figure 4b) .
Immunoassays of serum IL-6 and TNF-a Serum TNF-a concentrations were significantly raised in ZAtreated animals as compared to controls on both days 2 and 5 (Po0.05, two-way ANOVA) ( Figure 5 ). Serum IL-6 levels were uniformly raised on day 2 but dropped before day 5 (Po0.001, two-way ANOVA). On day 5, IL-6 levels from animals treated with 200 mg/ml dose were significantly higher than those from animals treated with 0.02 mg/ml dose (Po0.05, two-way ANOVA, Dunnett's post hoc test).
Aminoguanidine inhibition of ZA-induced adipogenesis
The addition of AG to the contralateral ZA-free chamber did not affect the extent of adipogenesis in that or the ZAcontaining ipsilateral when compared to constructs from animals receiving the same dose of ZA (Figures 6a and b) . However, when AG was combined with ZA in the same ipsilateral chamber there was a significantly reduction in the percentage and absolute adipose tissue content of constructs on both the ipsilateral and contralateral sides (Po0.005 percentage adipose tissue, Po0.001 absolute adipose tissue volume, two-way ANOVA, Dunnett's post hoc test). There was no significant difference in the Matrigel or fibrous tissue content of either group (Figure 6c) . The adipose tissue content of constructs from the group with ZA and AG in ipsilateral chamber was indistinguishable from controls that had not been exposed to ZA. There was no significant difference in adipose percentage or volume between ipsilateral and contralateral constructs from any group.
Long-term stability of inflammation induced adipose tissue Constructs increased in adipose content to 5.0570.73 ml (47.574.9%) in ipsilateral and 3.5970.85 ml (45.774.2%) in contralateral chambers at 12 weeks. Constructs remained compared to controls (ZA 0 mg/ml) on day 2 and 5, respectively). (b) IL-6 was uniformly raised on day 2 compared to day 5 (Po0.001, two-way ANOVA). On day 5 IL-6 levels were raised in the ZA 200 mg/ml group compared to the ZA 0.02 mg/ml group (*Po0.05) (n ¼ 4 per group).
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GPL Thomas et al stable for a further 12 weeks (Figure 7a) , showing a gradual but non-significant increase in adipose content of 5.5570.71 ml (61.472.5%) in ipsilateral and 4.4570.98 ml (5975.9%) in contralateral chambers at 24 weeks. Constructs from mice which had the chamber casing removed at 12 weeks were identical in volume and tissue content at 24 weeks to those constructs in which the chamber casing was retained (Figure 7b ).
Discussion
ZA induced neo-adipogenesis in a closed chamber model. This is an entirely novel finding. Although the inflammagen LPS has previously been shown to induced adipogenesis, this occurred in already established adipose tissue rather than a site devoid of pre-existing fat. 15 ZA induced inflammation in chambers in a dose-dependent manner. Very high concentrations of ZA (20 mg/chamber, from a pilot study, data not presented) caused a pronounced inflammatory response which infarcted the constructs and filled the chambers with purulent material. At high doses ZA is recognized to trigger a massive neutrophil-dominated influx of leukocytes when injected into closed spaces in vivo. 29, 30 Reducing the dose of ZA avoided this response but even at the lower range of concentrations used in the dose-response assay there was still evidence of a dose-dependent inflammatory effect. Systemically, serum TNF-a levels at early time points were elevated in high ZA dose as compared to low-dose mice and controls. Furthermore, even at 6 weeks, at the local level neutrophils, a cell population associated with the earlier phases of inflammation, 31 were significantly more numerous in constructs from animals receiving a high ZA dose. Serum IL-6 expression patterns were different from those of TNF-a. IL-6 levels in high-and low-dose ZA mice were not significantly different from controls, although they did differ between themselves. IL-6 responses to Toll-like receptor agonists (such as ZA) in vivo are complex. [32] [33] [34] As such it is not as reliable a marker of inflammation as TNF-a. Inflammation and adipogenesis GPL Thomas et al ZA induced adipogenesis indirectly, via inflammation. AG inhibited adipogenesis when combined with the ZA in the ipsilateral chamber but did not affect adipose tissue formation when added to the contralateral ZA-free chamber. Hence, AG did not inhibit adipogenesis directly, but rather by impairing ZA-induced inflammation, which in turn resulted in a reduced adipogenic response. The AG dose used was deliberately low, 40 mg/ml (70.4 mg/kg per 25 g animal), far less than that typically used in other studies (10-100 mg/kg [24] [25] [26] ). This was done with aim of inhibiting local iNOS within the chamber, while minimizing the possibility of systemic iNOS inhibition. Direct exposure of preadipocytes or adipocytes in culture to ZA or LPS activates Toll-like receptors, stimulating an innate immunity-mediated inflammatory response [35] [36] [37] that inhibits the differentiation. 37 Our in vitro data (not presented) support this finding.
Adipogenesis in subcutaneous plugs of Matrigel follows three distinct, but overlapping phases. 16 In the initial recruitment phase new blood vessels and fibroblast-like preadipocytes invade the virgin matrix. In the following phase preadipocytes proliferate within the matrix before differentiating into mature adipocytes in the final phase. We speculate that inflammation promotes and enhances the first two phases while impairing the final phase. Isolating Matrigel in a sealed chamber prevents the recruitment of local adipose precursor cells but still permits the recruitment of circulating populations via the vascular pedicle that passes through the chamber. We postulate that ZA-induced inflammation mobilizes circulating populations of adipose precursor cells, which are in turn trafficked into chambers along inflammation-generated chemokine gradients. Circulating cell populations with adipogenic potential that have been shown to be mobilized by, and engraft at, sites of inflammation include mesenchymal stem cells [38] [39] [40] [41] and fibrocytes. 42, 43 Furthermore, preadipocytes are recognized to express chemokine receptors and have been shown to migrate in response to inflammatory chemokines. 44, 45 Although no inflammatory stimulus was deliberately added to the contralateral chamber, the surgical dissection of the vascular pedicle ensures that some proinflammatory mediators, such as intracellular proteins from lysed cells, 46, 47 will be unavoidably present in the chamber. This low-grade inflammatory stimulus may be sufficient to traffic adipose precursor cells mobilized systemically by ZA, resulting in the new adipose tissue formation observed in the contralateral chamber.
Only at the very lowest dose of ZA (0.02 mg/ml) did the ipsilateral constructs contain more fat than the contralateral ones. Serum TNF-a and IL-6 levels from these animals compared to the high-dose group were decreased, implying a reduced systemic inflammatory response. If this resulted in fewer leukocytes and adipose precursor cells being mobilized, then at lower thresholds such cells may be preferentially directed to the more inflammatory ZA-containing chamber.
Inflammation will in all probability drive adipose precursor cell proliferation in vivo once recruitment to the construct has occurred, as several key inflammatory cytokines, including TNF-a 10,11 and IL-6, 11 have been found to be strongly mitogenic for preadipocytes in vitro. 48 However, a
proinflammatory cellular environment appears to induce preadipocytes to acquire an inflammatory phenotype. 48 Activated macrophage-secreted factors and inflammatory cytokines, particularly TNF-a, directly inhibit differentiation in vitro. [10] [11] [12] [13] [14] 48, 49 Adipose tissue generated by an inflammatory stimulus remained stable for up to 24 weeks. Adipocytes were not lost through subsequent tissue remodelling during the resolution of inflammation. To date, studies that report on the longterm stability of in vivo adipose constructs have been disappointing with many identifying tissue regression at later time points. 27, 57, 58 Macrophage foreign body reactions have been implicated in the late loss of maturing tissue constructs. 59 It is significant that here macrophage recruitment did not appear to result in tissue loss. This matches the physiology of obesity in which the expansion of the adipose tissue mass is associated with concomitant inflammatory cell recruitment, 7 and as such indicates that this is a useful in vivo model for studying adipogenesis in obesity. The model departs from the normal physiology of adipose tissue in that although the extracellular matrix of adipose tissue is rich in basement membrane, Matrigel is not an identical matrix. Further, the chamber by isolating its contents from surrounding tissues prevents local and paracrine factors influencing initial tissue development. In normal adipose tissue these factors undoubtedly play an important role in modulating adipogenesis. 60 The chamber casings were removed in one group in the long-term study at 12 weeks to expose constructs to local and paracrine influences from the abutting inguinal fat pad and subjected them to normal in vivo compressive forces. A previous study has indicated that adipogenesis is impaired by a lack of mechanical protection for the developing construct. 61 At 24 weeks, Inflammation and adipogenesis GPL Thomas et al constructs which had their chamber casings removed at 12 weeks were indistinguishable from constructs that had not, indicating that in this model once adipose tissue is formed it remains stable in the normal tissue environment and is largely unaffected by external factors. In summary, zymosan-induced inflammation stimulated adipose tissue formation in a Matrigel matrix-based in vivo chamber model both locally and at distant sites. This response was dose dependent. It is probable that inflammation promotes the mobilization of adipose precursor cells which home to the chambers and differentiates to form new adipose tissue. This suggests that the low-grade inflammation of adipose tissue observed in obesity may mobilize circulating adipose precursor cells which are recruited to the tissue in much the same manner as macrophages. 7 This would account for the ongoing adipose hyperplasia observed in obesity, which occurs despite the seemingly antiadipogenic actions of inflammatory cytokines.
